Disruption to GPs caused by a global IT outage may continue into the coming week, NHS England has said.

Officials found no evidence of silent infections in 35 Michigan dairy workers, but experts noted that much more data was necessary.Since an unusual bird flu outbreak was first detected in dairy cows in March, experts have warned that the virus could be infecting more farm workers than have been officially detected. Testing has been severely limited, constraining what health officials know about the ways that the virus is spreading from sick cows and contaminated equipment and how often it is spilling over into humans.In recent weeks, state and federal officials have been working to unravel part of that mystery: whether silent, undetected infections are occurring in farm workers. Officials in Michigan recently began testing the blood of 35 dairy workers for antibodies to the virus, which would provide evidence of past infection.On Friday, the Centers for Disease Control and Prevention shared preliminary results, which showed that none of the workers were carrying antibodies to the virus, known as H5N1. All worked on dairy farms in Michigan that had suffered outbreaks, and many worked directly with sick cows, the agency said.Dr. Natasha Bagdasarian, Michigan’s chief medical executive, noted that the study was small and that the results were not definitive. The farm workers tested were also volunteers, which means that they may not be representative of dairy workers more broadly.Still, she said, the results suggested that asymptomatic transmission “is likely not widespread, and that this disease is not something that is spreading with minimal contact.”In its online update, the C.D.C. noted that the results supported its approach to testing, which has focused on symptomatic people who had been in contact with sick animals.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe.

Researchers are only beginning to understand why some people embrace retirement while others won’t even consider it.Beth Bergmans liked working as a project manager for an online university based in Minnesota. “We are offering opportunities for people to advance in life — that brought some satisfaction,” she said. “And the people I work with are awesome.”Ms. Bergmans, 63, planned to stay on the job for two years, until she qualified for Medicare. But in recent months, something had shifted, subtly. In her fast-paced workplace, she began to find it harder to recall the details of recent meetings, to retrieve words and to filter out distractions. She took short breaks at her desk to recharge.“You find ways to adapt,” she said. “You use Post-it notes and whiteboards, and you spend more time prepping before a meeting.” Nobody complained or even seemed to notice, but Ms. Bergmans worried.“People don’t really talk about this, the fear that you’re starting to slip professionally,” she said. “The last thing I want is to crash and burn at the end because I didn’t recognize that it was time to stop.”So a couple of weeks ago, Ms. Bergmans told her manager that she would retire at the end of the year.Sometimes it works this way: People engaged in and proud of their careers, intending to continue past typical retirement ages, encounter internal or external difficulties and step aside, even if no one is urging them to resign or retire.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe.

30 minutes agoGetty ImagesThere is no evidence of a large rise in suicides in young patients attending a gender identity clinic in London,

Most GP practices in England have been disrupted by the

As patients consider drugs like Wegovy, Ozempic, Zepbound and Mounjaro to treat obesity, experts say the choices are not so simple.People with obesity now have a choice between two powerful drugs to help them lose weight. One is semaglutide, sold by Novo Nordisk as Wegovy for obesity treatment and as Ozempic for diabetes. The second, tirzepatide, is sold by Eli Lilly as Zepbound for obesity and as Mounjaro for diabetes. Many with neither obesity or diabetes take the drugs to get thinner.A recent study suggested that people lost more weight taking Mounjaro than they did taking Ozempic, and it may leave you wondering: Which should I take? And if I’m already taking one of them, should I switch?The answers, obesity medicine experts say, are not so simple. Here are some factors that can help sort out hype from realistic hope.Is one weight loss drug really better than the other?For now, it’s hard to say. All of the information available comes from “highly flawed studies,” said Dr. Diana Thiara, medical director of the weight loss clinic at the University of California, San Francisco.That includes the recent study comparing Mounjaro and Ozempic. Using electronic health records, the researchers reported that those taking Mounjaro lost an average of 15.3 percent of their weight after a year. Those taking Ozempic lost an average of 8.3 percent.While that sounds impressive, Dr. Susan Z. Yanovski, co-director of the Office of Obesity Research at the National Institute of Diabetes and Digestive and Kidney Diseases, said, “I wouldn’t make any decisions on my medical care based solely on a study like this.”We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe.

The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.Two top officials at Cassava Sciences — a small pharmaceutical company in Austin, Texas, embroiled in years of controversy over a proposed Alzheimer’s drug — have resigned.Remi Barbier, the chairman and chief executive, stepped down on Wednesday but will remain at Cassava “without duties or responsibilities” until September, according to a company statement.Lindsay Burns, Cassava’s chief scientist, who is married to Mr. Barbier, will also leave the company.In June, a neuroscientist at the City College of New York, Hoau-Yan Wang, was charged with fraud by a federal grand jury for allegedly falsifying data to obtain research grants from the National Institutes of Health.In collaboration with Dr. Burns, Dr. Wang published research studies in support of Cassava’s drug candidate for Alzheimer’s, called simufilam. It is currently in advanced trials, although more than five of Dr. Wang’s studies have been retracted or questioned by scientific journals.Mr. Barbier, Dr. Burns and Dr. Wang could not immediately be reached for comment.In a leaked report last fall, a City University of New York committee investigating the research faulted Dr. Burns for some of the errors discovered in the papers. Its members accused Dr. Wang of “longstanding and egregious misconduct in data management and record keeping.”In a regulatory filing earlier this month, Cassava reported that the Securities and Exchange Commission was investigating the company and two senior employees, who were not identified.Scientists have long criticized the methodological “oddities” in Cassava’s experiments with simufilam, citing suspicious figures in its published papers and questioning the underlying hypotheses about the drug’s mode of action.Dr. William Hu, an Alzheimer’s disease expert at Rutgers University and early critic of Cassava’s studies, said he hoped this was the first of many steps the company would take to make its research rigorous and transparent.Still, significant work needs to be done to “undo the harms from research misconduct,” he wrote in an email.Richard Barry, who has served on Cassava’s board of directors since 2021, has replaced Mr. Barbier as chairman of the board. The company is in the process of finding a new chief executive.Mr. Barry said in the statement that the board was committed to testing simufilam in Alzheimer’s patients with “transparency, accountability and highest ethical business practices.”A spokeswoman at the Food and Drug Administration said it did not discuss ongoing clinical trials or products in development.

43 minutes agoGetty ImagesMillions of lives are at risk unless urgent and radical action is taken to stop drug-resistant malaria spreading in Africa, scientists warn.

24 minutes agoGetty ImagesEven as Covid hit, the government and its health officials were bullish in their confidence about their ability to cope.

A Public Health Service employee, he turned whistle-blower after learning of decades-long research involving hundreds of poor, infected Black men who were left untreated.Peter Buxtun, a whistle-blower who in 1972 exposed a 40-year government experiment to track the effects of syphilis in Black men in Alabama — who were neither told that they had the disease nor offered treatment — died on May 18 in Rocklin, Calif., near Sacramento. He was 86.His death, in a memory care center, was from complications of Alzheimer’s disease, said John K. Seidts, a close friend. The death was first reported on Monday by The Associated Press, to which Mr. Buxtun had turned over his files and which in 1972 published the first news articles about his disclosures.Exposure of the Tuskegee Study, as the federal research was known, created a political furor that shut it down, but the study cast a long, dark shadow as an episode of official racism embedded in government policy. It was one of the worst medical ethics scandals in U.S. history, tarnishing the do-no-harm image of doctors and, especially, sowing mistrust of the medical establishment among many African Americans.Mr. Buxtun, the son of a Jewish father who fled Czechoslovakia before World War II to escape persecution, was working as a venereal disease investigator for the U.S. Public Health Service in San Francisco in 1965 when he overheard a co-worker talking about the Tuskegee Study taking place in rural Alabama.One of his first acts was to visit a library to research the crimes of Nazi doctors in World War II.He contacted the Communicable Disease Center in Atlanta (now the Centers for Disease Control and Prevention), which had cooperated with the Public Health Service in overseeing the Tuskegee Study. The agency, making no effort to conceal the study from a government employee, sent him a manila envelope stuffed with reports.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe.